Childhood Sjögren syndrome: Insights from adults and animal models

Current Opinion in Rheumatology

Volumn 25, Issue 5, 2013, Pages 651-657

  Lieberman, Scott M ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

animal models; children; diagnosis; pathogenesis; Sj gren syndrome; treatment

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTIMUSCARINIC ACETYLCHOLINE RECEPTOR TYPE 3; AQUAPORIN 1; AQUAPORIN 5; ARTIFICIAL TEAR; AUTOANTIBODY; BETA INTERFERON; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; INTERFERON; LAMBDA INTERFERON; MUSCARINIC RECEPTOR; OMEGA INTERFERON; RITUXIMAB; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ADULT; ANIMAL MODEL; ANTIBODY SPECIFICITY; B LYMPHOCYTE; BIOLOGICAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILDHOOD DISEASE; CLINICAL FEATURE; DIAGNOSTIC ERROR; EPITHELIUM CELL; FATIGUE; HUMAN; IMMUNOGENETICS; IMMUNOPATHOGENESIS; LACRIMAL GLAND FUNCTION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RESEARCH DIAGNOSTIC CRITERIA; REVIEW; SALIVARY GLAND; SJOEGREN SYNDROME; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIRAL GENE THERAPY; XEROSTOMIA;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; GENETIC THERAPY; HUMANS; IMMUNOLOGIC FACTORS; MESENCHYMAL STEM CELL TRANSPLANTATION; SJOGREN'S SYNDROME; T-LYMPHOCYTE SUBSETS;

EID: 84881543030     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328363ed23     Document Type: Review

References (52)

1. Bartunkova J, Sediva A, Vencovsky J, Tesar V. Primary Sjogren's syndrome in children and adolescents: proposal for diagnostic criteria. Clin Exp Rheumatol 1999; 17:381-386.
2. Houghton K, Malleson P, Cabral D, et al. Primary Sjogren's syndrome in children and adolescents: are proposed diagnostic criteria applicable? J Rheumatol 2005; 32:2225-2232.
3. Baszis K, Toib D, Cooper M, et al. Recurrent parotitis as a presentation of primary pediatric Sjogren syndrome. Pediatrics 2012; 129:e179-e182.
4. Bogdanovic R, Basta-Jovanovic G, Putnik J, et al. Renal involvement in primary Sjogren syndrome of childhood: case report and literature review. Mod Rheumatol 2013; 23:182-189.
5. Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64:475-487.
6. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: a systematic review. JAMA 2010; 304:452-460.
7. Gottenberg JE, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 2012.
8. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren's syndrome treated with rituximab. Ann Rheum Dis 2012; 71:1297-1302.
9. Mekinian A, Ravaud P, Larroche C, et al. Rituximab in central nervous system manifestations of patients with primary Sjogren's syndrome: results from the AIR registry. Clin Exp Rheumatol 2012; 30:208-212.
10. St Clair EW, Levesque MC, Luning Prak ET, et al. Rituximab therapy for primary Sjogren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013.
11. Hamza N, Bootsma H, Yuvaraj S, et al. Persistence of immunoglobulinproducing cells in parotid salivary glands of patients with primary Sjogren's syndrome after B cell depletion therapy. Ann Rheum Dis 2012; 71:1881-1887.
12. Baum BJ, Alevizos I, Zheng C, et al. Early responses to adenoviral-mediated transfer of the aquaporin-1 cDNA for radiation-induced salivary hypofunction. Proc Natl Acad Sci U S A 2012; 109:19403-19407.
13. Yin H, Nguyen CQ, Samuni Y, et al. Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NODAec1Aec2 mouse model of Sjogren's syndrome. Arthritis Res Ther 2012; 14:R40.
14. Lee BH, Carcamo WC, Chiorini JA, et al. Gene therapy using IL-27 ameliorates Sjogren's syndrome-like autoimmune exocrinopathy. Arthritis Res Ther 2012; 14:R172.
15. Khalili S, Liu Y, Kornete M, et al. Mesenchymal stromal cells improve salivary function and reduce lymphocytic infiltrates in mice with Sjogren's-like disease. PLoS One 2012; 7:e38615.
16. Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood 2012; 120:3142-3151.
17. Ice JA, Li H, Adrianto I, et al. Genetics of Sjogren's syndrome in the genomewide association era. J Autoimmun 2012; 39:57-63.
18. Bolstad AI, Le Hellard S, Kristjansdottir G, et al. Association between genetic variants in the tumour necrosis factor/lymphotoxin alpha/lymphotoxin beta locus and primary Sjogren's syndrome in Scandinavian samples. Ann Rheum Dis 2012; 71:981-988.
19. Cay HF, Sezer I, Dogan S, et al. Polymorphism in the TNF-alpha gene promoter at position -1031 is associated with increased circulating levels of TNF-alpha, myeloperoxidase and nitrotyrosine in primary Sjogren's syndrome. Clin Exp Rheumatol 2012; 30:843-849.
20. Ambatipudi KS, Swatkoski S, Moresco JJ, et al. Quantitative proteomics of parotid saliva in primary Sjogren's syndrome. Proteomics 2012; 12:3113-3120.
21. Kosenda K, Ichii O, Otsuka S, et al. BXSB/MpJ-Yaa mice develop autoimmune dacryoadenitis with the appearance of inflammatory cell marker mRNAs in the lacrimal fluid. Clin Experiment Ophthalmol 2013; doi: 10.1111/ ceo.12083. [Epub ahead of print]
22. Tandon M, Gallo A, Jang SI, et al. Deep sequencing of short RNAs reveals novel microRNAs in minor salivary glands of patients with Sjogren's syndrome. Oral Dis 2012; 18:127-131.
23. Horvath S, Nazmul-Hossain AN, Pollard RP, et al. Systems analysis of primary Sjogren's syndrome pathogenesis in salivary glands identifies shared pathways in human and a mouse model. Arthritis Res Ther 2012; 14:R238.
24. Yao Y, Liu Z, Jallal B, et al. Type I interferons in Sjogren's syndrome. Autoimmun Rev 2013; 12:558-566.
25. Brkic Z, Maria NI, van Helden-Meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013; 72:728-735.
26. SzczerbaBM,RybakowskaPD,Dey P, et al.Type I interferon receptordeficiency prevents murine Sjogren's syndrome. J Dent Res 2013; 92:444-449.
27. Hall JC, Casciola-Rosen L, Berger AE, et al. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012; 109:17609-17614.
28. Moriyama M, Hayashida JN, Toyoshima T, et al. Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjogren's syndrome. Clin Exp Immunol 2012; 169:17-26.
29. Maehara T, Moriyama M, Hayashida JN, et al. Selective localization of T helper subsets in labial salivary glands from primary Sjogren's syndrome patients. Clin Exp Immunol 2012; 169:89-99.
30. Bombardieri M, Barone F, Lucchesi D, et al. Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice. J Immunol 2012; 189:3767-3776.
31. Risselada AP, Looije MF, Kruize AA, et al. The role of ectopic germinal centers in the immunopathology of primary sjogren's syndrome: a systematic review. Semin Arthritis Rheum 2013; 42:368-376.
32. Alunno A, Bistoni O, Bartoloni E, et al. IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjogren's syndrome. Ann Rheum Dis 2013; 72:286-292.
33. Cheng KT, Alevizos I, Liu X, et al. STIM1 and STIM2 protein deficiency in T lymphocytes underlies development of the exocrine gland autoimmune disease, Sjogren's syndrome. Proc Natl Acad Sci U S A 2012; 109:14544-14549.
34. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J Autoimmun 2010; 34:400-407.
35. Thabet Y, Le Dantec C, Ghedira I, et al. Epigenetic dysregulation in salivary glands from patients with primary Sjogren's syndrome may be ascribed to infiltrating B cells. J Autoimmun 2013; 41:175-181.
36. Varin MM, Guerrier T, Devauchelle-Pensec V, et al. In Sjogren's syndrome, B lymphocytes induce epithelial cells of salivary glands into apoptosis through protein kinase C delta activation. Autoimmun Rev 2012; 11:252-258.
37. Pertovaara M, Bootorabi F, Kuuslahti M, et al. Carbonic anhydrase autoantibodies and sicca symptoms in primary Sjogren s syndrome. Clin Exp Rheumatol 2012; 30:456-457.
38. de Jong H, de Jager W, Wenting-van Wijk M, et al. Increased immune reactivity towards human hsp60 in patients with primary Sjogren's syndrome is associated with increased cytokine levels and glandular inflammation. Clin Exp Rheumatol 2012; 30:594-595.
39. El Annan J, Jiang G, Wang D, et al. Elevated immunoglobulin to tissue KLK11 in patients with Sjogren syndrome. Cornea 2013; 32:e90-e93.
40. Shen L, Suresh L, Lindemann M, et al. Novel autoantibodies in Sjogren's syndrome. Clin Immunol 2012; 145:251-255.
41. Sumida T, Iizuka M, Asashima H, et al. Pathogenic role of anti-M3 muscarinic acetylcholine receptor immune response in Sjogren's syndrome. Presse Med 2012; 41:e461-466.
42. Nakamura Y, Wakamatsu E, Matsumoto I, et al. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenileonset Sjogren syndrome. Ann Rheum Dis 2008; 67:136-137.
43. Tsuboi H, Nakamura Y, Iizuka M, et al. Generation and functional analysis of monoclonal antibodies against the second extracellular loop of human M3 muscarinic acetylcholine receptor. Mod Rheumatol 2012; 22:264-271.
44. Jin M, Hwang SM, Davies AJ, et al. Autoantibodies in primary Sjogren's syndrome patients induce internalization of muscarinic type 3 receptors. Biochim Biophys Acta 2012; 1822:161-167.
45. Reina S, Sterin-Borda L, Borda E. Anti-M(3) peptide IgG from Sjogren's syndrome triggers apoptosis in A253 cells. Cell Immunol 2012; 275:33-41.
46. Lee BH, Gauna AE, Perez G, et al. Autoantibodies against muscarinic type 3 receptor in Sjogren's syndrome inhibit aquaporin 5 trafficking. PLoS One 2013; 8:e53113.
47. He J, Qiang L, Ding Y, et al. The role of muscarinic acetylcholine receptor type 3 polypeptide (M3RP205-220) antibody in the saliva of patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2012; 30:322-326.
48. Okuma A, Hoshino K, Ohba T, et al. Enhanced apoptosis by disruption of the STAT3-Ikb-z-signaling pathway in epithelial cells induces Sjogren's syndrome- like autoimmune disease. Immunity 2013; 38:450-460.
49. Barrera MJ, Sanchez M, Aguilera S, et al. Aberrant localization of fusion receptors involved in regulated exocytosis in salivary glands of Sjogren's syndrome patients is linked to ectopic mucin secretion. J Autoimmun 2012; 39:83-92.
50. Castro I, Aguilera S, Brockhausen I, et al. Decreased salivary sulphotransferase activity correlated with inflammation and autoimmunity parameters in Sjogren's syndrome patients. Rheumatology (Oxford) 2012; 51:482-490.
51. Manoussakis MN, Tsinti M, Kapsogeorgou EK, Moutsopoulos HM. The salivary gland epithelial cells of patients with primary Sjogren's syndrome manifest significantly reduced responsiveness to 17beta-estradiol. J Autoimmun 2012; 39:64-68.
52. Barrera MJ, Bahamondes V, Sepulveda D, et al. Sjogren's syndrome and the epithelial target: a comprehensive review. J Autoimmun 2013; 42:7-18.